1 / 2
Custom Cargrilintide CAS 1415456-99-3 - Quality China Suppliers and Factory for Peptide Solutions Manufacturer, Quotes
Product Description
Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity.
Mechanism & Efficacy
Cagrilintide is a long‑acting synthetic analogue of the pancreatic hormone amylin, classified as an amylin receptor agonist. It targets amylin receptors and related pathways that regulate appetite, satiety, gastric emptying, and post‑meal glucose metabolism. By activating these pathways, Cagrilintide helps reduce food intake, prolong feelings of fullness, and support metabolic balance in research settings. It is also being studied in combination with GLP‑1 receptor agonists such as semaglutide for enhanced weight‑loss and metabolic effects.
Dosage & Research Use
Cagrilintide is evaluated primarily in clinical and preclinical research for metabolic and obesity studies. In major clinical programs such as the Phase 2 and Phase 3 “REDEFINE” trials, cagrilintide has been administered as a subcutaneous injection once weekly with a gradual dose escalation protocol to minimize gastrointestinal side effects. Target doses in these protocols frequently reached 2.4 mg per week, with initial titration starting from lower doses such as 0.3–0.5 mg during the first weeks of treatment.
Frequently Asked Questions
Q
What is Cagrilintide?
Cagrilintide is a long-acting synthetic analogue of the pancreatic hormone amylin, classified as an amylin receptor agonist, primarily evaluated for metabolic and obesity studies.
Q
How does Cagrilintide assist in weight management?
It targets amylin receptors to regulate appetite, satiety, gastric emptying, and post-meal glucose metabolism, which helps reduce food intake and prolong feelings of fullness.
Q
Is Cagrilintide used as a standalone treatment?
While it has its own efficacy, it is currently being developed and studied in combination with GLP-1 receptor agonists, such as semaglutide, to achieve enhanced and sustained weight loss.
Q
How is Cagrilintide administered in clinical trials?
In major clinical programs like the “REDEFINE” trials, it is administered as a subcutaneous injection once weekly.
Q
What is the typical target dosage of Cagrilintide?
Research protocols frequently reach a target dose of 2.4 mg per week, with initial titrations starting at lower doses of 0.3–0.5 mg.
Q
Why is a gradual dose escalation protocol necessary?
A gradual dose escalation from a lower starting dose is utilized to help minimize potential gastrointestinal side effects during the initial weeks of treatment.
